ePROMs in oligometastatic SABR patients

  • Research type

    Research Study

  • Full title

    Optimising toxicity data collection in patients receiving stereotactic ablative radiotherapy (SABR) for oligometastases by the inclusion of patient reported outcomes (PROMs)

  • IRAS ID

    236955

  • Contact name

    Louise Murray

  • Contact email

    louise.murray8@nhs.net

  • Sponsor organisation

    University of Leeds

  • Duration of Study in the UK

    1 years, 5 months, 28 days

  • Research summary

    The purpose of this study is to ask patients with cancer about treatment-related side effects and investigate if this information can be collected electronically rather than using paper and pens.

    Stereotactic ablative radiotherapy (SABR) is a relatively new type of treatment that delivers a very high dose of radiotherapy, very accurately to a small area of cancer. SABR can be used when cancer returns in a limited number of places in the body (termed oligometastatic cancer). While SABR is thought to be effective in controlling oligometastatic cancer in some patients, with few side effects, as assessed by doctors, there has not been a lot of work evaluating side effects according to patients themselves. It is very important to assess how treatment affects patients directly, as what doctors think patients experience, and what patients themselves experience, can be very different. Most patients currently receive SABR within an NHS England programme, called Commissioning through Evaluation. Within this programme, patient experiences are only assessed in a brief 5-question questionnaire. More detailed questionnaires exist to assess patient experience and short and long-term treatment-related side effects. This study would use more detailed questionnaires to get a better understanding of how SABR for oligometastases affects patients.

    We would like to investigate if patients are happy to complete such questionnaires using electronic devices, such as tablet computers, smart phones and home computers. QTool is an electronic survey tool, which is being developed so that it works easily on all electronic devices. Patients would complete questionnaires at scheduled clinic visits prior to SABR, 6 weeks, 3 months and 6 months after SABR and from home at 3 weeks after SABR. Tablet computers will be available in the clinic waiting room if required. Paper questionnaires will be available for those who prefer this method of questionnaire completion.

  • REC name

    Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

  • REC reference

    18/YH/0106

  • Date of REC Opinion

    4 May 2018

  • REC opinion

    Further Information Favourable Opinion